CRYOPORT, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.13 USD | -2.06% |
|
-7.72% | +4.13% |
| Apr. 05 | North American Morning Briefing : Investors on -2- | DJ |
| Mar. 15 | UBS Adjusts Cryoport Price Target to $17 From $14.50, Maintains Neutral Rating | MT |
Financials (USD)
| Sales 2024 * | 246M | Sales 2025 * | 272M | Capitalization | 810M |
|---|---|---|---|---|---|
| Net income 2024 * | -67M | Net income 2025 * | -55M | EV / Sales 2024 * | 3.64 x |
| Net Debt 2024 * | 86.07M | Net Debt 2025 * | 130M | EV / Sales 2025 * | 3.45 x |
| P/E ratio 2024 * |
-13.3
x | P/E ratio 2025 * |
-16.9
x | Employees | 1,025 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.54% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cryoport, Inc.
More recommendations
More press releases
| 1 day | -2.06% | ||
| 1 week | -7.72% | ||
| Current month | -8.87% | ||
| 1 month | -2.48% | ||
| 3 months | +11.63% | ||
| 6 months | +38.45% | ||
| Current year | +4.13% |
1 week
15.59
17.55
1 month
15.5920.11
Current year
13.9320.11
1 year
9.0024.17
3 years
9.0086.30
5 years
9.0086.30
10 years
1.0386.30
| Managers | Title | Age | Since |
|---|---|---|---|
Jerrell Shelton
CEO | Chief Executive Officer | 76 | 12-10-21 |
| Director of Finance/CFO | 59 | 11-06-26 | |
Mark Sawicki
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Berman
BRD | Director/Board Member | 81 | 14-12-31 |
Linda Baddour
BRD | Director/Board Member | 63 | 21-03-14 |
Jerrell Shelton
CEO | Chief Executive Officer | 76 | 12-10-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.10% | 12 M€ | -.--% | - | |
| 0.06% | 509 M€ | -.--% | ||
| 0.02% | 9 M€ | -.--% | - | |
| 0.02% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 16.13 | -2.06% | 514,632 |
| 24-04-18 | 16.47 | -1.91% | 435,163 |
| 24-04-17 | 16.79 | -1.29% | 274,694 |
| 24-04-16 | 17.01 | -0.06% | 377,360 |
| 24-04-15 | 17.02 | -2.63% | 478,732 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotes
Cryoport, Inc. is engaged in supply chain solutions for cell and gene therapies. The Companyâs supply chain solutions enable manufacturers, contract manufacturers (CDMOâs), contract research organizations (CROâs), developers, and researchers to carry out their business with certainty. The Company provides a broad array of supply chain solutions for the life sciences industry. Through its platform of critical products and solutions, including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, the Company is enabling the future of medicine worldwide, through its systems, compliant procedures, and approach to supply chain management. Its products and services include Cryoport Express Shippers, Cryoport ELITE Shipper Systems, Cryoport Consulting Services, Cryoport Bioservices, CRYOGENE, CRYOPDP Temperature-controlled Logistics, Cryoport Cryoshuttle, IntegriCell Services, Tec4Med, and others.
Sector
Air Freight & Logistics
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
16.13
USD
Average target price
18.33
USD
Spread / Average Target
+13.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.13% | 810M | |
| +34.57% | 5.58B | |
| +16.45% | 3.98B | |
| +10.46% | 2.22B | |
| +5.06% | 976M | |
| +92.63% | 915M | |
| -15.56% | 545M | |
| -32.37% | 500M | |
| -4.35% | 458M | |
| -15.06% | 420M |
- Stock Market
- Equities
- CYRX Stock
